carbamazepine has been researched along with Weight Gain in 24 studies
Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.
carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.
Weight Gain: Increase in BODY WEIGHT over existing weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Changes in body weight were evaluated in 349 patients from a study comparing efficacy of add-on therapy with tiagabine (TGB), carbamazepine (CBZ) or phenytoin (PHT)." | 9.09 | Total percentage body weight changes during add-on therapy with tiagabine, carbamazepine and phenytoin. ( Bertrand, ME; Deaton, RL; Hogan, RE; Sommerville, KW, 2000) |
| " This paper presents an analysis of body weight data gathered during a randomized trial comparing valproate with carbamazepine in 260 children aged 4-15 years with newly-diagnosed epilepsy." | 9.08 | Weight gain with valproate or carbamazepine--a reappraisal. ( Easter, D; O'Bryan-Tear, CG; Verity, C, 1997) |
| "We have analyzed the records retrospectively and interviewed 70 adult patients attending an epilepsy clinic on VPA mono- or polytherapy followed over a median of 27 months (range 3-189), as well as 20 patients on carbamazepine (CBZ) monotherapy." | 9.08 | Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. ( Corman, CL; Guberman, AH; Leung, NM, 1997) |
| "This retrospective longitudinal study included 85 VPA-treated and 93 carbamazepine (CBZ)-treated (as a reference) young patients with epilepsy." | 7.83 | Cytochrome P450 2C19 polymorphisms and valproic acid-induced weight gain. ( Ishitsu, T; Kajiwara, A; Nakagawa, K; Noai, M; Oniki, K; Saruwatari, J; Soraoka, H; Tanamachi, Y, 2016) |
| "Studies of the effect of oxcarbazepine (OXC) on body growth of children with epilepsy are rare and their results are controversial." | 7.83 | Weight gain in children on oxcarbazepine monotherapy. ( Attilakos, A; Garoufi, A; Katsarou, E; Koemtzidou, E; Kossiva, L; Soldatou, A; Tsentidis, C; Vartzelis, G, 2016) |
| "We evaluated the serum leptin and insulin as predictors of weight gain in children receiving long-term treatment with valproate (VPA), carbamazepine (CBZ), lamotrigine (LTG)." | 7.75 | States of serum leptin and insulin in children with epilepsy: risk predictors of weight gain. ( Fida, NM; Hamed, EA; Hamed, SA, 2009) |
| " This retrospective study of children with epilepsy, aged <12 years at enrollment, examined weight gain associated with valproic acid or carbamazepine monotherapy." | 7.74 | Lack of valproic acid-associated weight gain in prepubertal children. ( Baumann, RJ; Espinosa, PS; Mendiondo, MS; Robertson, WC; Salazar, JC; Yu, L, 2008) |
| "The effect of aging on carbamazepine (CBZ) plasma level/dose ratio was evaluated retrospectively in 15 children who were receiving CBZ monotherapy and who were followed up for at least 3 years." | 7.68 | A within-subject analysis of carbamazepine disposition related to development in children with epilepsy. ( Albani, F; Baruzzi, A; Contin, M; Riva, R, 1992) |
| "Four young patients who developed weight gain induced by carbamazepine therapy are described." | 7.68 | Weight gain, increased appetite, and excessive food intake induced by carbamazepine. ( Eshel, Y; Lampl, Y; Rapaport, A; Sarova-Pinhas, I, 1991) |
| "Oxcarbazepine was developed to attempt to reduce the side effects that have traditionally been observed with antiepileptic drugs that induce the hepatic enzyme system." | 5.33 | Central hypothyroidism with oxcarbazepine therapy. ( Carney, P; Miller, J, 2006) |
| "Diurnal weight gain was abnormal among 149 institutionalized chronically psychotic patients." | 5.28 | Antipsychotic drugs, lithium, carbamazepine, and abnormal diurnal weight gain in psychosis. ( Godleski, L; Harrington, D; Hundley, P; Vieweg, V; Yank, G, 1989) |
| "Changes in body weight were evaluated in 349 patients from a study comparing efficacy of add-on therapy with tiagabine (TGB), carbamazepine (CBZ) or phenytoin (PHT)." | 5.09 | Total percentage body weight changes during add-on therapy with tiagabine, carbamazepine and phenytoin. ( Bertrand, ME; Deaton, RL; Hogan, RE; Sommerville, KW, 2000) |
| " This paper presents an analysis of body weight data gathered during a randomized trial comparing valproate with carbamazepine in 260 children aged 4-15 years with newly-diagnosed epilepsy." | 5.08 | Weight gain with valproate or carbamazepine--a reappraisal. ( Easter, D; O'Bryan-Tear, CG; Verity, C, 1997) |
| "We have analyzed the records retrospectively and interviewed 70 adult patients attending an epilepsy clinic on VPA mono- or polytherapy followed over a median of 27 months (range 3-189), as well as 20 patients on carbamazepine (CBZ) monotherapy." | 5.08 | Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. ( Corman, CL; Guberman, AH; Leung, NM, 1997) |
| "This retrospective longitudinal study included 85 VPA-treated and 93 carbamazepine (CBZ)-treated (as a reference) young patients with epilepsy." | 3.83 | Cytochrome P450 2C19 polymorphisms and valproic acid-induced weight gain. ( Ishitsu, T; Kajiwara, A; Nakagawa, K; Noai, M; Oniki, K; Saruwatari, J; Soraoka, H; Tanamachi, Y, 2016) |
| "Studies of the effect of oxcarbazepine (OXC) on body growth of children with epilepsy are rare and their results are controversial." | 3.83 | Weight gain in children on oxcarbazepine monotherapy. ( Attilakos, A; Garoufi, A; Katsarou, E; Koemtzidou, E; Kossiva, L; Soldatou, A; Tsentidis, C; Vartzelis, G, 2016) |
| "We evaluated the serum leptin and insulin as predictors of weight gain in children receiving long-term treatment with valproate (VPA), carbamazepine (CBZ), lamotrigine (LTG)." | 3.75 | States of serum leptin and insulin in children with epilepsy: risk predictors of weight gain. ( Fida, NM; Hamed, EA; Hamed, SA, 2009) |
| " This retrospective study of children with epilepsy, aged <12 years at enrollment, examined weight gain associated with valproic acid or carbamazepine monotherapy." | 3.74 | Lack of valproic acid-associated weight gain in prepubertal children. ( Baumann, RJ; Espinosa, PS; Mendiondo, MS; Robertson, WC; Salazar, JC; Yu, L, 2008) |
| "The effect of aging on carbamazepine (CBZ) plasma level/dose ratio was evaluated retrospectively in 15 children who were receiving CBZ monotherapy and who were followed up for at least 3 years." | 3.68 | A within-subject analysis of carbamazepine disposition related to development in children with epilepsy. ( Albani, F; Baruzzi, A; Contin, M; Riva, R, 1992) |
| "Four young patients who developed weight gain induced by carbamazepine therapy are described." | 3.68 | Weight gain, increased appetite, and excessive food intake induced by carbamazepine. ( Eshel, Y; Lampl, Y; Rapaport, A; Sarova-Pinhas, I, 1991) |
| "Usually, no adverse effects are observed in breastfed infants whose mothers are treated with the anti-epileptic carbamazepine." | 1.48 | Maternal Carbamazepine Therapy and Unusual Adverse Effects in a Breastfed Infant. ( Antonucci, R; Cherchi, C; Cuzzolin, L; Locci, C; Manconi, A; Oggiano, AM, 2018) |
| "Weight gain was found to be lower in the elderly for antipsychotic drugs, in particular for olanzapine." | 1.39 | Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland. ( Baumann, P; Greil, W; Grohmann, R; Häberle, A; Schuhmann, T, 2013) |
| "Weight gain was seen in 66." | 1.36 | Modification in body weight associated with antiepileptic drugs. ( Gaspari, CN; Guerreiro, CA, 2010) |
| "Absence status was aggravated with carbamazepine and generalised tonic-clonic seizures were not controlled with ethosuximide." | 1.36 | Unilateral continuous subclinical paroxysmal activity: an unusual finding in a patient with recurrent absence status. ( Genton, P; Velizarova, R, 2010) |
| "Oxcarbazepine was developed to attempt to reduce the side effects that have traditionally been observed with antiepileptic drugs that induce the hepatic enzyme system." | 1.33 | Central hypothyroidism with oxcarbazepine therapy. ( Carney, P; Miller, J, 2006) |
| "Juvenile myoclonic epilepsy is a common, under-recognised form of epilepsy which is best treated with sodium valproate." | 1.29 | Juvenile myoclonic epilepsy: diagnosis, management and outcome. ( Buchanan, N; Sharpe, C, 1995) |
| "Diurnal weight gain was abnormal among 149 institutionalized chronically psychotic patients." | 1.28 | Antipsychotic drugs, lithium, carbamazepine, and abnormal diurnal weight gain in psychosis. ( Godleski, L; Harrington, D; Hundley, P; Vieweg, V; Yank, G, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (12.50) | 18.7374 |
| 1990's | 9 (37.50) | 18.2507 |
| 2000's | 5 (20.83) | 29.6817 |
| 2010's | 7 (29.17) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antonucci, R | 1 |
| Cuzzolin, L | 1 |
| Manconi, A | 1 |
| Cherchi, C | 1 |
| Oggiano, AM | 1 |
| Locci, C | 1 |
| Greil, W | 1 |
| Häberle, A | 1 |
| Schuhmann, T | 1 |
| Grohmann, R | 1 |
| Baumann, P | 1 |
| Noai, M | 1 |
| Soraoka, H | 1 |
| Kajiwara, A | 1 |
| Tanamachi, Y | 1 |
| Oniki, K | 1 |
| Nakagawa, K | 1 |
| Ishitsu, T | 1 |
| Saruwatari, J | 1 |
| Garoufi, A | 1 |
| Vartzelis, G | 1 |
| Tsentidis, C | 1 |
| Attilakos, A | 1 |
| Koemtzidou, E | 1 |
| Kossiva, L | 1 |
| Katsarou, E | 1 |
| Soldatou, A | 1 |
| Hamed, SA | 1 |
| Fida, NM | 1 |
| Hamed, EA | 1 |
| Espinosa, PS | 1 |
| Salazar, JC | 1 |
| Yu, L | 1 |
| Mendiondo, MS | 1 |
| Robertson, WC | 1 |
| Baumann, RJ | 1 |
| Prodam, F | 1 |
| Bellone, S | 1 |
| Casara, G | 1 |
| De Rienzo, F | 1 |
| Grassino, EC | 1 |
| Bonsignori, I | 1 |
| Demarchi, I | 1 |
| Rapa, A | 1 |
| Radetti, G | 1 |
| Bona, G | 1 |
| Gaspari, CN | 1 |
| Guerreiro, CA | 1 |
| Velizarova, R | 1 |
| Genton, P | 1 |
| Miller, J | 1 |
| Carney, P | 1 |
| Sharpe, C | 1 |
| Buchanan, N | 1 |
| Baptista, T | 1 |
| Weiss, SR | 1 |
| Post, RM | 1 |
| Easter, D | 1 |
| O'Bryan-Tear, CG | 1 |
| Verity, C | 1 |
| Corman, CL | 1 |
| Leung, NM | 1 |
| Guberman, AH | 1 |
| Schaller, JL | 1 |
| Behar, D | 1 |
| Hogan, RE | 1 |
| Bertrand, ME | 1 |
| Deaton, RL | 1 |
| Sommerville, KW | 1 |
| Ranganath, HN | 1 |
| Tu, JB | 1 |
| Hartridge, C | 1 |
| Izawa, J | 1 |
| Albani, F | 1 |
| Riva, R | 1 |
| Contin, M | 1 |
| Baruzzi, A | 1 |
| Coxhead, N | 1 |
| Silverstone, T | 1 |
| Cookson, J | 1 |
| Lampl, Y | 1 |
| Eshel, Y | 1 |
| Rapaport, A | 1 |
| Sarova-Pinhas, I | 1 |
| Brady, KT | 1 |
| Vieweg, WV | 1 |
| Godleski, LS | 1 |
| Shannon, C | 1 |
| Hundley, PL | 1 |
| Yank, GR | 1 |
| Vieweg, V | 1 |
| Godleski, L | 1 |
| Hundley, P | 1 |
| Harrington, D | 1 |
| Yank, G | 1 |
1 review available for carbamazepine and Weight Gain
| Article | Year |
|---|---|
Weight gain associated with psychotropic drugs.
Topics: Antidepressive Agents; Antipsychotic Agents; Carbamazepine; Humans; Lithium; Monoamine Oxidase Inhib | 1989 |
4 trials available for carbamazepine and Weight Gain
| Article | Year |
|---|---|
Weight gain with valproate or carbamazepine--a reappraisal.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Cross-Over Studies; Dose-Respon | 1997 |
Weight gain in epileptic patients during treatment with valproic acid: a retrospective study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Male; Middle Aged | 1997 |
Total percentage body weight changes during add-on therapy with tiagabine, carbamazepine and phenytoin.
Topics: Anticonvulsants; Body Weight; Carbamazepine; Double-Blind Method; Drug Therapy, Combination; Epileps | 2000 |
Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder.
Topics: Adult; Aged; Bipolar Disorder; Carbamazepine; Double-Blind Method; Electrocardiography; Female; Huma | 1992 |
19 other studies available for carbamazepine and Weight Gain
| Article | Year |
|---|---|
Maternal Carbamazepine Therapy and Unusual Adverse Effects in a Breastfed Infant.
Topics: Adult; Anticonvulsants; Bottle Feeding; Breast Feeding; Carbamazepine; Child of Impaired Parents; Ep | 2018 |
Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; An | 2013 |
Cytochrome P450 2C19 polymorphisms and valproic acid-induced weight gain.
Topics: Adolescent; Anticonvulsants; Body Mass Index; Carbamazepine; Child; Cytochrome P-450 CYP2C19; Epilep | 2016 |
Weight gain in children on oxcarbazepine monotherapy.
Topics: Adolescent; Anticonvulsants; Body Mass Index; Carbamazepine; Child; Child, Preschool; Epilepsy; Fema | 2016 |
States of serum leptin and insulin in children with epilepsy: risk predictors of weight gain.
Topics: Adolescent; Age Factors; Anticonvulsants; Body Mass Index; Carbamazepine; Case-Control Studies; Chil | 2009 |
Lack of valproic acid-associated weight gain in prepubertal children.
Topics: Adolescent; Anticonvulsants; Body Height; Body Mass Index; Body Weight; Carbamazepine; Child; Child, | 2008 |
Ghrelin levels are reduced in prepubertal epileptic children under treatment with carbamazepine or valproic acid.
Topics: Age Factors; Anticonvulsants; Body Height; Body Mass Index; Carbamazepine; Child; Depression, Chemic | 2010 |
Modification in body weight associated with antiepileptic drugs.
Topics: Adult; Anticonvulsants; Body Mass Index; Carbamazepine; Epilepsy; Female; Humans; Male; Valproic Aci | 2010 |
Unilateral continuous subclinical paroxysmal activity: an unusual finding in a patient with recurrent absence status.
Topics: Adult; Anticonvulsants; Brain; Carbamazepine; Diagnosis, Differential; Dose-Response Relationship, D | 2010 |
Central hypothyroidism with oxcarbazepine therapy.
Topics: Adolescent; Anticonvulsants; Body Height; Carbamazepine; Child; Dose-Response Relationship, Drug; Fe | 2006 |
Juvenile myoclonic epilepsy: diagnosis, management and outcome.
Topics: Adolescent; Adult; Alcohol Drinking; Anticonvulsants; Carbamazepine; Epilepsies, Myoclonic; Female; | 1995 |
Carbamazepine attenuates cocaine-induced increases in dopamine in the nucleus accumbens: an in vivo dialysis study.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carbamazepine; Cocaine; Dialysis; Dopamine; Homovanillic Ac | 1993 |
Carbamazepine and methylphenidate in ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Carbamazepine; Drug Administration Schedu | 1999 |
Carbamazepine and weight gain.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Female; Humans; Male; Weight Gain | 2000 |
Psychopharmacogenetic aspects of Prader-Willi syndrome.
Topics: Adolescent; Aggression; Appetite Depressants; Behavior Therapy; Carbamazepine; Combined Modality The | 1992 |
A within-subject analysis of carbamazepine disposition related to development in children with epilepsy.
Topics: Adolescent; Aging; Carbamazepine; Child; Child Development; Child, Preschool; Dose-Response Relation | 1992 |
Weight gain, increased appetite, and excessive food intake induced by carbamazepine.
Topics: Adolescent; Appetite; Carbamazepine; Child; Eating; Epilepsy; Female; Humans; Male; Weight Gain | 1991 |
Normalization of abnormal diurnal weight gain among chronically psychotic geriatric patients. Is abnormal diurnal weight gain a risk factor in chronic psychosis?
Topics: Adult; Aged; Antipsychotic Agents; Blood Pressure; Carbamazepine; Chronic Disease; Circadian Rhythm; | 1989 |
Antipsychotic drugs, lithium, carbamazepine, and abnormal diurnal weight gain in psychosis.
Topics: Adult; Antipsychotic Agents; Body Water; Carbamazepine; Circadian Rhythm; Female; Humans; Lithium; M | 1989 |